The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 18, 2022

Filed:

Oct. 16, 2020
Applicant:

Sun Pharma Advanced Research Company Ltd, Mumbai, IN;

Inventors:

Gaurav Sanjivkumar Sheth, Vadodara, IN;

Sabbirhusen Yusufbhai Chimanwala, Vadodara, IN;

Tushar Mukund Jarag, Vadodara, IN;

Aishwarya Hampiholi, Pune, IN;

Saikat Maity, Medinipur, IN;

Prabal Sengupta, Vadodara, IN;

Gulamnizami Abdulsattar Qureshi, Vadodara, IN;

Umesh Vishnu Chaudhari, Vadodara, IN;

Raj Gopal Venkat, Hyderabad, IN;

V. S. N. Murty Kadiyala, Vadodara, IN;

Sairam V V M Kalapatapu, Hyderabad, IN;

Vaibhav Jain, Sagar, IN;

Trinadha Rao Chitturi, Vadodara, IN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 409/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 209/08 (2006.01); C07D 209/18 (2006.01); C07D 209/42 (2006.01); C07D 213/74 (2006.01); C07D 213/81 (2006.01); C07D 295/182 (2006.01); C07D 493/08 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); C07D 209/08 (2013.01); C07D 209/18 (2013.01); C07D 209/42 (2013.01); C07D 213/74 (2013.01); C07D 213/81 (2013.01); C07D 295/182 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 409/12 (2013.01); C07D 493/08 (2013.01);
Abstract

The present invention relates to novel compounds useful as malic enzyme (ME) inhibitors, processes for their preparation and use of these compounds for the therapeutic treatment of disorders mediated by ME such as cancers (e.g. pancreatic ductal adenocarcinoma (PDAC)) in humans. The novel compounds have a structure according to Formula I or a pharmaceutically acceptable salt, stereoisomer or deuterated analog thereof, wherein X, R, Rand Y are as described herein.


Find Patent Forward Citations

Loading…